MENU
JUN 06, 2017 8:00 AM PDT

The new generation in immunoassays

Sponsored by: Thermo Fisher Scientific
Speaker
  • Senior R&D Manager and Immunoassay Strategy Lead, Biosciences Division, Thermo Fisher Scientific
    Biography
      David's Ph.D. and postdoctoral work focused on the study of G protein-coupled receptor signaling and thrombosis. Following his academic training, he led multiplexed immunoassay automation efforts at a Luminex® partnering company. In 2009, David joined Thermo Fisher Scientific working on the development of novel immunoassay platforms such as the ProtoPlex™ Immune Response Assay. Now as Sr. Manager and immunoassay strategy lead, David pursues next-gen immunoassay platform development which includes working with translational investigators to identify serum-based biomarkers in cancer, autoimmunity, and inflammation.

    Abstract

    DATE: June 6, 2017
    TIME: 8:00am PT, 11:00am ET

    Early detection of protein biomarkers is critical to the study of human disease (cancer, neurobiology, inflammation/autoimmunity, etc). Basic research scientists, as well as translational investigators seek sensitive protein quantitation tools that provide low-level detection of disease relevant protein analytes. The enzyme-­linked immunosorbant assay (ELISA) first developed in the 1970s and slightly improved upon over the years, is still considered the gold standard for specific protein quantitation. However, large sample consumption, limited sensitivity, and laborious workflows associated with ELISA methods leave room for improvement and new innovation. 

    Thermo Fisher Scientific, the worldwide leader in life science tools for researchers, is unveiling an affordable new platform for the next generation of high­sensitivity, ready-to-use immunoassays. Featuring serum compatible, TaqMan™ based proximity ligation assay (PLA) and Siteclick™ antibody labeling technologies, this new assay combines the analyte specificity of high affinity antibody-antigen binding with the signal detection and amplification of real-time PCR. Not only does this assay technique allow measurement of low expressing proteins that we may not have otherwise been able to detect, but it also provides an easy method to verify gene expression at a protein level. 

    In this webinar, we will address the following items related to this new platform: 

    • Small sample consumption – uses 2-5 µL of sample (for example, 2uL vs 150uL for triplicate wells with other methods)  
    • High-sensitivity – detect low levels of proteins with greater sensitivity than other traditional methods 
    • Large dynamic range – 5 logs or greater minimizes guessing associated with sample dilutions
    • Fast, easy workflow – no wash steps, 2 hours from sample to answer. Step 1: Mix samples with antibodies and incubate. Step 2: Add master mix reagents and place into real time PCR instrument.
    • No proprietary instrument to purchase - Runs on any real time PCR instrument – no need for specialized equipment
    • Includes intuitive free cloud-enabled software – for robust data analysis and statistical groupwise comparison
    • Publishing - The importance of validation for publishing purposes
    • Q & A with the expert

     


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    DEC 05, 2019 5:00 AM PST
    C.E. CREDITS
    DEC 05, 2019 5:00 AM PST
    DATE: December 5, 2019TIME: 5:00am PST, 8:00am EST The diagnosis of an active infection by the hepatitis B virus (HBV) relies on testing for the HBV surface antigen (HBsAg). Ov...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources